Art. 87 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 28 Jan 2022cited 17×
1.

The Commission shall be assisted by the Standing Committee on Medicinal Products for Human Use established by Article 121 of Directive 2001/83/EC. That committee shall be a committee within the meaning of Regulation (EU) No 182/2011 of the European Parliament and of the Council [Regulation (EU) No 182/2011 of the European Parliament and of the Council of 16 February 2011 laying down the rules and general principles concerning mechanisms for control by Member States of the Commission’s exercise of implementing powers (OJ L 55, 28.2.2011, p. 13).].

2.

Where reference is made to this paragraph, Article 5 of Regulation (EU) No 182/2011 shall apply.

The 10 that are cited most themselves, of 17.

  • Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision

    On 19 December 2013, the Commission submitted a draft implementing decision granting marketing authorisation for ‘Tecfidera – Dimethyl fumarate’, a medicinal product for human use, to the Standing Committee on Medicinal Products for …

    5 May 2021 · 62018TJ0611

  • Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 Decembe…Lawamends

  • Regulation (EU) 2019/5Lawamends

  • Commission Implementing Regulation (EU) No 520/2012 of 19 June 2012 on the performance o…Law

    … 1.], y, en particular, su artículo 87, apartado 2 bis, Vista la Directiva 2001/83/CE del Parlamento Europeo y del Consejo, de 6 de noviembre de 2001, por la que se establece un código comunitario sobre medicamentos para uso humano [DO L …

  • Arrêt du Tribunal (huitième chambre) du 2 mars 2022. Debregeas et associés Pharma (D & A Pharma) contre Commission européenne et Agence euroDecision

    Aux termes de l’article 10 du règlement n o 726/2004, la Commission, assistée par le CHMP, prépare un projet de décision dans les quinze jours suivant la réception de l’avis du CHMP. Ce projet de décision est transmis aux États …

    2 Mar 2022 · 62020TJ0556

  • Judgment of the General Court (Sixth Chamber) of 28 October 2020. Pharma Mar, SA v European Commission.Decision

    The draft decision was discussed by the Standing Committee on Medicinal Products for Human Use set up by Article 121 of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to …

    28 Oct 2020 · 62018TJ0594

  • Council Regulation (EC) No 1905/2005 of 14 November 2005 amending Regulation (EC) No 297…1Law

    … the amounts of the fees established by this Regulation shall be adopted in accordance with the procedure laid down in Article 87(2) of Regulation (EC) No 726/2004, with exception of the updating provided for in the fifth paragraph of this …

  • Regulation (EC) No 219/2009 of the European Parliament and of the Council of 11 March 20…Lawamends

  • Judgment of the General Court (Fifth Chamber, Extended Composition) of 24 September 2025. Sanofi BV, anciennement Genzyme Europe BV v EuropeDecision

    The first subparagraph of Article 10(1) of Regulation No 726/2004 provides that, following receipt of the CHMP’s opinion, the Commission is to prepare a draft decision on the MA application. The fourth subparagraph of Article 10(1) of …

    24 Sep 2025 · 62022TJ0483

  • Opinion of Advocate General Sharpston delivered on 31 January 2013. Novartis Pharma GmbH v Apozyt GmbH.Decision

    Articles 4 to 10 set out the procedure relating to applications for the authorisation of a medicinal product. Applications are to be submitted to the European Medicines Agency established under the Regulation, [See Articles 1 and 4(1).] …

    31 Jan 2013 · 62011CC0535